Skip To Main Content
Pangaea Oncology on Muck Rack

Pangaea Oncology

As seen in: Nature, PLOS Medicine, Frontiers, Frontiers in Immunology, BMC Cancer, Genome Medicine, Molecular Cancer, The Lancet, EClinicalMedicine, Cancer Research and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pangaea

Contact Pangaea, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

|
By Giulia Notini, Vita-Salute San Raffaele, Pangaea Oncology, Quiron Group
| PLOS Medicine Verified
Loading metrics Open Access Perspective Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online. See all article types » ? This is an uncorrected proof. Citation: Notini G, Bianchini G, Perez-Garcia JM, Cortés J (2026) Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy. PLoS Med 23(1): e1004930.
Open in Who Shared Issue with article?

Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection

|
By Pangaea Oncology, Quirónsalud Group
| Frontiers in Immunology
1 Introduction Breast cancer (BC) is the most common cancer in women and the most prevalent worldwide according to the World Health Organization (WHO). In 2022, 2.3 million women were diagnosed with BC and it has a growing incidence (1, 2). In the same year, about 670,000 women died from the disease (1).
Open in Who Shared Issue with article?

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

|
By C. Saura, J. Cortes, Pangaea Oncology, Quiron Group
Key words metastatic breast cancer HER2+ trastuzumab deruxtecan pooled analysis Get full text access Log in, subscribe or purchase for full access. References 1. Wolff, A.C. ∙ Hammond, M.E. ∙ Hicks, D.G. ... Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol. 2013; 31:3997-4013 2. Pernas, S.
Open in Who Shared Issue with article?
See all 21 articles